Immunome Statistics
Total Valuation
Immunome has a market cap or net worth of $2.38 billion. The enterprise value is $1.73 billion.
Important Dates
The last earnings date was Tuesday, March 3, 2026, after market close.
| Earnings Date | Mar 3, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Immunome has 113.13 million shares outstanding. The number of shares has increased by 48.96% in one year.
| Current Share Class | 113.13M |
| Shares Outstanding | 113.13M |
| Shares Change (YoY) | +48.96% |
| Shares Change (QoQ) | +7.93% |
| Owned by Insiders (%) | 1.20% |
| Owned by Institutions (%) | 91.50% |
| Float | 94.26M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 342.94 |
| Forward PS | n/a |
| PB Ratio | 3.75 |
| P/TBV Ratio | 3.75 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 249.34 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 14.69, with a Debt / Equity ratio of 0.01.
| Current Ratio | 14.69 |
| Quick Ratio | 14.53 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -52.09% and return on invested capital (ROIC) is -32.47%.
| Return on Equity (ROE) | -52.09% |
| Return on Assets (ROA) | -28.98% |
| Return on Invested Capital (ROIC) | -32.47% |
| Return on Capital Employed (ROCE) | -33.55% |
| Weighted Average Cost of Capital (WACC) | 16.29% |
| Revenue Per Employee | $39,215 |
| Profits Per Employee | -$1.20M |
| Employee Count | 177 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +125.99% in the last 52 weeks. The beta is 2.19, so Immunome's price volatility has been higher than the market average.
| Beta (5Y) | 2.19 |
| 52-Week Price Change | +125.99% |
| 50-Day Moving Average | 22.74 |
| 200-Day Moving Average | 15.09 |
| Relative Strength Index (RSI) | 41.23 |
| Average Volume (20 Days) | 1,067,784 |
Short Selling Information
The latest short interest is 16.04 million, so 14.18% of the outstanding shares have been sold short.
| Short Interest | 16.04M |
| Short Previous Month | 15.77M |
| Short % of Shares Out | 14.18% |
| Short % of Float | 17.02% |
| Short Ratio (days to cover) | 9.29 |
Income Statement
In the last 12 months, Immunome had revenue of $6.94 million and -$212.39 million in losses. Loss per share was -$2.43.
| Revenue | 6.94M |
| Gross Profit | -170.35M |
| Operating Income | -214.11M |
| Pretax Income | -212.39M |
| Net Income | -212.39M |
| EBITDA | -211.65M |
| EBIT | -214.11M |
| Loss Per Share | -$2.43 |
Full Income StatementBalance Sheet
The company has $653.48 million in cash and $3.86 million in debt, with a net cash position of $649.63 million or $5.74 per share.
| Cash & Cash Equivalents | 653.48M |
| Total Debt | 3.86M |
| Net Cash | 649.63M |
| Net Cash Per Share | $5.74 |
| Equity (Book Value) | 634.34M |
| Book Value Per Share | 5.61 |
| Working Capital | 615.79M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$190.92 million and capital expenditures -$9.69 million, giving a free cash flow of -$200.60 million.
| Operating Cash Flow | -190.92M |
| Capital Expenditures | -9.69M |
| Free Cash Flow | -200.60M |
| FCF Per Share | -$1.77 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -3,084.76% |
| Pretax Margin | -3,059.99% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Immunome does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -48.96% |
| Shareholder Yield | -48.96% |
| Earnings Yield | -8.92% |
| FCF Yield | -8.43% |
Analyst Forecast
The average price target for Immunome is $32.80, which is 55.89% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $32.80 |
| Price Target Difference | 55.89% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (5Y) | 143.84% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Immunome has an Altman Z-Score of 10.78 and a Piotroski F-Score of 2.
| Altman Z-Score | 10.78 |
| Piotroski F-Score | 2 |
